Tonghua Dongbao Pharmaceutical (600867.SH): Recombinant Human Insulin Injection receives foreign drug registration certificate.

Tonghua Dongbao Pharmaceutical (600867.SH) announced that the company recently received the drug registration certificate for the insulin injection Penodian approved by the Food and Drug Supervisory Authority of the Republic of Indonesia (registration number: DKI2570600143A1). Penodian insulin injection is a rapid-acting insulin analog that takes effect 10-20 minutes after subcutaneous injection, with a duration of action of 3-5 hours, mainly controlling postprandial blood sugar. Penodian insulin is typically administered immediately before meals, and can also be given immediately after meals when necessary. Penodian insulin has a rapid onset and short duration of action, and is usually used in combination with long-acting insulin to achieve both basal and postprandial blood sugar control in patients. The issuance of the drug registration certificate for Penodian insulin injection by the Food and Drug Supervisory Authority of the Republic of Indonesia indicates that Tonghua Dongbao Pharmaceutical is authorized to sell Penodian insulin injection in Indonesia. This will help enrich the company's international product line, enhance its brand image, expand international business, accelerate the layout in emerging markets, and improve the company's competitiveness in the international market.